Bragar Eagel & Squire, P.C. is investigating potential claims against HCA Healthcare, Inc. on behalf of HCA stockholders. The investigation concerns whether HCA violated federal securities laws or engaged in other unlawful business practices. On July 14, 2026, HCA sharply lowered its full-2026 profit guidance, citing an unfavorable shift in payer mix that impacted revenue by approximately $400 million in the second quarter. Following that news, HCA's stock price fell $27.14 per share, or 6.95%, to close at $363.60 per share. Stockholders who purchased or acquired HCA shares and suffered a loss are encouraged to contact the firm.
HCA Healthcare, Inc.HCA lowered full-year profit guidance due to unfavorable payer mix, causing stock to drop 6.95%.
